Somnomed Limited (AU:SOM)
ASX:SOM
SOM Stock Chart & Stats
AU$0.62
AU$0.03(6.67%)
At close: 4:00 PM EST
AU$0.62
AU$0.03(6.67%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$0.95
Previous CloseN/A
Volume51.81K
Average Volume (3M)705.41K
Market Cap
AU$135.83M
Enterprise ValueAU$120.86M
Total Cash (Recent Filing)AU$18.03M
Total Debt (Recent Filing)AU$14.01M
Price to Earnings (P/E)52.9
Beta1.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.99Price Target Upside60.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinician-led DistributionA clinician-led sales model creates durable demand channels through prescribers and dental specialists. Long-term relationships with dentists and sleep physicians raise switching costs, support recurrent device orders and training, and underpin steady device adoption over multiple quarters.
Consistent Revenue GrowthSustained top-line growth (~18% reported) indicates increasing market penetration and clinician adoption. Over a 2-6 month horizon this trend supports scale benefits, better fixed-cost absorption and the opportunity to invest incrementally in product and distribution without relying on short-term market moves.
Strong Cash Generation And Gross MarginsA large improvement in free cash flow and a ~60% gross margin show the core product is cash-generative and manufactured efficiently. Durable cash conversion gives the company flexibility to fund operations, R&D and clinician engagement even while net profits lag, reducing refinancing risk.
Bears Say
Persistent UnprofitabilityNegative net and EBIT margins are a structural issue: ongoing losses constrain reinvestment and shareholder returns. Unless operational leverage or pricing improves, persistent unprofitability will limit strategic flexibility and could force capital raises or cost cuts over the medium term.
Low/negative Return On EquityNegative ROE shows the company is not generating acceptable returns on invested capital despite low financial leverage. This signals deeper issues—pricing, operating costs or scale—and weakens long-term shareholder value unless management improves margins or achieves faster profitable growth.
Demand Tied To Clinician Adoption & ReimbursementRevenue depends on clinician prescribing behavior, diagnosis/referral flows and reimbursement policies—structural factors that change slowly and are often outside company control. Adverse reimbursement shifts or slow clinician adoption can materially depress durable demand and revenue visibility.
Somnomed Limited News
SOM FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.37 and its highest was AU$0.94 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$135.83M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,083,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.28%
12-Months-Change
Fundamentals
Return on Equity
-5.31%
Trailing 12-Months
Asset Growth
14.75%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obstructive sleep apnea; SomnoBrux, a dental guard for the treatment of teeth grinding damage; SomMorning Repositioner, which help return mandible back to its pre-treatment centric position; and SomTabs for cleaning oral devices. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SOM Company Deck
SOM Earnings Call
Q2 2026
0:00 / 0:00
SOM Stock 12 Month Forecast
Average Price Target
AU$0.99
▲(60.29% Upside)
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---